Envestnet Asset Management Inc. Acquires New Stake in Abivax SA Sponsored ADR $ABVX

Envestnet Asset Management Inc. bought a new stake in shares of Abivax SA Sponsored ADR (NASDAQ:ABVX) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 20,300 shares of the company’s stock, valued at approximately $1,723,000.

Several other institutional investors also recently bought and sold shares of ABVX. Boothbay Fund Management LLC lifted its position in shares of Abivax by 52.5% during the second quarter. Boothbay Fund Management LLC now owns 870,438 shares of the company’s stock worth $6,659,000 after purchasing an additional 299,770 shares in the last quarter. Woodline Partners LP grew its holdings in shares of Abivax by 319.5% in the first quarter. Woodline Partners LP now owns 201,924 shares of the company’s stock valued at $1,262,000 after purchasing an additional 153,788 shares in the last quarter. Nan Fung Trinity HK Ltd. purchased a new stake in Abivax during the 3rd quarter worth approximately $8,606,000. Federated Hermes Inc. acquired a new stake in Abivax during the 3rd quarter worth approximately $8,448,000. Finally, Stempoint Capital LP acquired a new stake in Abivax during the 2nd quarter worth approximately $671,000. 47.91% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts have commented on ABVX shares. BTIG Research restated a “buy” rating and issued a $150.00 price target on shares of Abivax in a research note on Wednesday. Truist Financial set a $140.00 target price on Abivax in a research note on Monday, November 24th. Oppenheimer set a $131.00 price target on Abivax in a report on Thursday, January 8th. Citizens Jmp lifted their price objective on Abivax from $114.00 to $131.00 and gave the company a “market outperform” rating in a research note on Tuesday, December 16th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Abivax in a research report on Wednesday, January 21st. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Abivax has a consensus rating of “Moderate Buy” and a consensus target price of $134.75.

Abivax Stock Up 1.5%

Shares of NASDAQ ABVX opened at $121.28 on Friday. The business has a 50-day moving average of $124.29 and a two-hundred day moving average of $106.07. The company has a market capitalization of $9.59 billion, a price-to-earnings ratio of -29.01 and a beta of 0.79. Abivax SA Sponsored ADR has a 1 year low of $4.77 and a 1 year high of $148.83. The company has a debt-to-equity ratio of 0.03, a current ratio of 7.86 and a quick ratio of 7.86.

Abivax (NASDAQ:ABVX) last released its quarterly earnings data on Monday, December 15th. The company reported ($2.46) EPS for the quarter. The firm had revenue of ($4.92) million during the quarter. On average, analysts forecast that Abivax SA Sponsored ADR will post -2.83 earnings per share for the current fiscal year.

Abivax Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.